P-Glycoprotein

A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE).

Also Known As:

Networked: 5596 relevant articles (205 outcomes, 830 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Beijnen, Jos H: 36 articles (12/2015 - 04/2004)
2.	Ambudkar, Suresh V: 30 articles (10/2015 - 08/2002)
3.	Löscher, Wolfgang: 28 articles (06/2015 - 04/2002)
4.	Lage, Hermann: 28 articles (04/2015 - 02/2002)
5.	Gottesman, Michael M: 25 articles (09/2015 - 07/2002)
6.	Efferth, Thomas: 24 articles (12/2015 - 01/2003)
7.	Schinkel, Alfred H: 22 articles (12/2015 - 03/2003)
8.	Potschka, Heidrun: 21 articles (01/2014 - 04/2002)
9.	Elmquist, William F: 20 articles (11/2015 - 05/2007)
10.	Molnár, Joseph: 20 articles (11/2015 - 01/2002)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2007 - "curtisii extract may play an important role as a P-gp modulator as used in vitro and may be effective in the treatment of multidrug-resistant cancers. " 07/10/2015 - "In vivo detection of the emergence of P-glycoprotein (Pgp) mediated multidrug resistance in tumors could be beneficial for patients treated with anticancer drugs. " 05/12/2015 - "Because of the enhanced intracellular and nuclear drug accumulation through effective inhibition of the P-gp efflux transporter, DOX/TQR coloaded nanovesicles showed significantly improved tumor cell inhibitory efficiency, especially for drug-resistant cells. " 05/01/2015 - "Nanocarriers are beneficial in the transport of chemotherapeutics by their ability to bypass the P-gp efflux in cancers. " 03/01/2015 - "This therapeutic improvement in response to Dox was attributed to the significant, sequence-specific P-gp downregulation in excised tumors mediated by the DOPE-PEI formulations. "
2.	Breast Neoplasms (Breast Cancer) 08/01/2015 - "We conclude that peloruside is highly effective in preventing the growth of lung and P-glycoprotein-overexpressing breast tumors in vivo and that further therapeutic development is warranted. " 01/01/1996 - "p-gp is frequently expressed in patients with untreated breast cancer, with p-gp-positive patients being at significantly greater risk for disease recurrence. " 11/01/2014 - "Exosomes are effective in transferring drug resistance as well as P-gp from drug-resistant breast cancer cells to sensitive ones. " 06/01/2010 - "This work demonstrates that the ACMS-GOX are effective in circumventing P-gp-mediated MDR in breast cancer cells." 06/01/2015 - "Various studies examined whether AEDs are substrates of P-glycoprotein (Pgp; MDR1; ABCB1), whereas information about the potential role of breast cancer resistance protein (BCRP; ABCG2) is scanty. "
3.	Alzheimer Disease (Alzheimer's Disease) 08/01/2011 - "In this study, we aimed to investigate the possibility of P-gp as a potential therapeutic target for Alzheimer's disease by examining the impact of P-gp up-regulation on the clearance of Aβ, a neuropathological hallmark of Alzheimer's disease. " 08/01/2011 - "Our results elucidate the importance of targeting Aβ clearance via P-gp up-regulation, which will be effective in slowing or halting the progression of Alzheimer's disease." 12/01/2012 - "Thus, VDR activation up-regulates Mdr1/MDR1 and P-gp protein in isolated rat brain capillaries and rodent and human brain microvascular endothelia, implicating a role for VDR in increasing the brain clearance of P-gp substrates, including hAβ(42), a plaque-forming precursor in Alzheimer's disease." 05/01/2004 - "These findings led us to hypothesize that P-gp might be involved in the clearance of Abeta in normal aging and particularly in Alzheimer's disease (AD). " 01/01/2012 - "The purpose of this study was to assess the effects of C1236T, G2677T/A and C3435T single-nucleotide polymorphisms in ABCB1 on blood-brain barrier P-glycoprotein function in healthy subjects and patients with Alzheimer's disease. "
4.	Leukemia 04/01/1997 - "In 31 acute leukemia patients at initial diagnosis, mdr1 or mdr3 P-gp expression correlated significantly to an outcome of complete remission (CR). " 12/01/1995 - "Complete remission (CR) was achieved in 12/14 (85%) children's and 9/11 (81%) adults' P-gp (+) leukemia cases. " 08/01/2010 - "miR-138 could significantly down-regulate the expression of P-glycoprotein, Bcl-2, and the transcription of the multidrug resistance gene 1. Further study of the biological functions of miR-138 might be helpful for developing possible strategies to treat leukemia." 12/01/2000 - "The remission rate of acute leukemia patients is significantly lower in P-gp+ patients than in P-gp- patients. " 02/01/2014 - "The present study aimed to explore the effect of As2O3 on the expression and regulation of P-gp in leukemia cells, and elucidate the mechanism of the reversal of drug resistance. "
5.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/11/2012 - "Univariate analysis revealed that there was a significant difference between complete remission rates for acute myelogenous leukemia patients depending on their blast cell expressions, between LRP positive versus negative, P-gp positive versus negative, and LRP/P-gp double positive versus other groups. " 06/01/1994 - "In order to further define the role of the MDR1 gene in acute myeloid leukemia (AML), we determined the association between the presence of P-glycoprotein on leukemic cells and the efficacy of therapy in patients with AML. " 11/18/2010 - "Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999." 02/01/1999 - "To study the immunophenotype and P-glycoprotein expression in CD7 positive adult acute myeloid leukemia (CD7+ AML). " 02/01/1996 - "From these results, if we can clarify the mechanism of MDR and the relationship between MDR and cytogenetic or clinical features of ANLL with further study, P-gp expression may become a useful marker for predicting the outcome of ANLL."

Related Drugs and Biologics

1.	P-Glycoprotein
2.	Paclitaxel (Taxol)
3.	Doxorubicin (Adriamycin)
4.	Carbon Monoxide
5.	Amyloid (Amyloid Fibrils)
6.	Proteins (Proteins, Gene)
7.	Adenosine Triphosphate (ATP)
8.	Multidrug Resistance-Associated Proteins
9.	Daunorubicin (Cerubidine)
10.	Small Interfering RNA (siRNA)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Remission Induction
3.	Therapeutics
4.	Heterologous Transplantation (Xenotransplantation)
5.	Combination Drug Therapy (Combination Chemotherapy)